Royal London Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.76M | Sell |
53,804
-3,171
| -6% | -$399K | 0.02% | 507 |
|
|
2025
Q1 | $6.3M | Buy |
56,975
+5,442
| +11% | +$602K | 0.01% | 530 |
|
|
2024
Q4 | $7.03M | Hold |
51,533
| – | – | 0.02% | 494 |
|
|
2024
Q3 | $5.94M | Buy |
51,533
+6,060
| +13% | +$698K | 0.01% | 531 |
|
|
2024
Q2 | $6.26M | Hold |
45,473
| – | – | 0.02% | 497 |
|
|
2024
Q1 | $6.27M | Buy |
45,473
+13,225
| +41% | +$1.82M | 0.02% | 507 |
|
|
2023
Q4 | $4.25M | Hold |
32,248
| – | – | 0.01% | 565 |
|
|
2023
Q3 | $3.63M | Buy |
32,248
+2,370
| +8% | +$267K | 0.01% | 571 |
|
|
2023
Q2 | $2.82M | Buy |
+29,878
| New | +$2.82M | 0.01% | 597 |
|